ATM and cancer: The first ATM inhibitor, utilised in in vivo studies was KU59403 (KuDOS Pharmaceuticals, now AstraZeneca, UK), and although it was not cytotoxic to human cancer cell lines, it significantly increased the cytotoxicity of topoisomerase I and II agents: camptothecin, etoposide and doxorubicin [93].